Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 678194, 5 pages
http://dx.doi.org/10.1155/2015/678194
Research Article

Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study

1Molecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, 55131 Mainz, Germany
2Department of Pediatrics, Johannes Gutenberg University (JGU) Medical Center, 55131 Mainz, Germany
3Department of Psychology, Technical University of Darmstadt, 64283 Darmstadt, Germany

Received 20 October 2014; Revised 9 January 2015; Accepted 10 January 2015

Academic Editor: Jack R. Wall

Copyright © 2015 E. Kampmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Marcocci, L. Bartalena, F. Bogazzi, M. Panicucci, and A. Pinchera, “Studies on the occurrence of ophthalmopathy in Graves' disease,” Acta Endocrinologica, vol. 120, no. 4, pp. 473–478, 1989. View at Google Scholar · View at Scopus
  2. G. B. Bartley and C. A. Gorman, “Diagnostic criteria for Graves' ophthalmopathy,” The American Journal of Ophthalmology, vol. 119, no. 6, pp. 792–795, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. M. P. Mourits, L. Koornneef, W. M. Wiersinga, M. F. Prummel, A. Berghout, and R. van der Gaag, “Clinical criteria for the assessment of disease activity in Graves' ophthalmology: a novel approach,” The British Journal of Ophthalmology, vol. 73, no. 8, pp. 639–644, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. S. C. Werner, “Modification of the classification of the eye changes of Graves' disease,” The American Journal of Ophthalmology, vol. 83, no. 5, pp. 725–727, 1977. View at Publisher · View at Google Scholar · View at Scopus
  5. W. M. Wiersinga, “Quality of life in Graves' ophthalmopathy,” Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 26, no. 3, pp. 359–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. A. Ponto, G. Hommel, S. Pitz, H. Elflein, N. Pfeiffer, and G. J. Kahaly, “Quality of life in a German graves orbitopathy population,” The American Journal of Ophthalmology, vol. 152, no. 3, pp. 483–490, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Bartalena, A. Pinchera, and C. Marcocci, “Management of Graves' ophthalmopathy: reality and perspectives,” Endocrine Reviews, vol. 21, no. 2, pp. 168–199, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Y. Goh, S. C. Ho, L. L. Seah, K. S. Fong, and D. H. C. Khoo, “Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Grave's disease differ and suggest ophthalmopathy is a multiantigenic disease,” Clinical Endocrinology, vol. 60, no. 5, pp. 600–607, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Li, J. Kim, T. Diana, R. Klasen, P. D. Olivo, and G. J. Kahaly, “A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity,” Clinical and Experimental Immunology, vol. 173, no. 3, pp. 390–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Kamijo, H. Murayama, T. Uzu, K. Togashi, P. D. Olivo, and G. J. Kahaly, “Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease,” Thyroid, vol. 21, no. 12, pp. 1295–1299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Leschik, T. Diana, P. D. Olivo et al., “Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins,” The American Journal of Clinical Pathology, vol. 139, no. 2, pp. 192–200, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. G. J. Kahaly, O. Shimony, Y. N. Gellman et al., “Regulatory T-cells in Graves' orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 422–429, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. K. Eckstein, A. Finkenrath, A. Heiligenhaus et al., “Dry eye syndrome in thyroid-associated ophthalmopathy: Lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies,” Acta Ophthalmologica Scandinavica, vol. 82, no. 3, pp. 291–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. A. K. Eckstein, M. Plicht, H. Lax et al., “Thyrotropin receptor autoantibodies are independent risk factors for graves' ophthalmopathy and help to predict severity and outcome of the disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3464–3470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Y. Jang, D. Y. Shin, E. J. Lee, Y. J. Choi, S. Y. Lee, and J. S. Yoon, “Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy,” Yonsei Medical Journal, vol. 54, no. 4, pp. 1033–1039, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. N. Gerding, J. W. C. van der Meer, M. Broenink, O. Bakker, W. M. Wiersinga, and M. F. Prummel, “Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy,” Clinical Endocrinology, vol. 52, no. 3, pp. 267–271, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. D. H. C. Khoo, S. C. Ho, L. L. Seah et al., “The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy,” Thyroid, vol. 9, no. 12, pp. 1175–1180, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Subekti, A. Boedisantoso, N. D. Moeloek, S. Waspadji, and M. Mansyur, “Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy,” Acta Medica Indonesiana, vol. 44, no. 2, pp. 114–121, 2012. View at Google Scholar · View at Scopus
  19. L. R. Dragan, S. R. Seiff, and D. C. Lee, “Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy,” Ophthalmic Plastic and Reconstructive Surgery, vol. 22, no. 1, pp. 13–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. D. Lytton, Y. Li, P. D. Olivo, L. D. Kohn, and G. J. Kahaly, “Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulin,” Clinical & Experimental Immunology, vol. 162, no. 3, pp. 438–446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. R. S. Bahn, “Graves' ophthalmopathy,” The New England Journal of Medicine, vol. 362, no. 8, pp. 726–738, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M.-C. Many, S. Costagliola, M. Detrait, J.-F. Denef, G. Vassart, and M. Ludgate, “Development of an animal model of autoimmune thyroid eye disease,” Journal of Immunology, vol. 162, no. 8, pp. 4966–4974, 1999. View at Google Scholar · View at Scopus
  23. J. Y. Noh, N. Hamada, Y. Inoue, Y. Abe, K. Ito, and K. Ito, “Thyroid-stimulating antibody is related to graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease,” Thyroid, vol. 10, no. 9, pp. 809–813, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Bartalena, L. Baldeschi, A. J. Dickinson et al., “Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy,” Thyroid, vol. 18, no. 3, pp. 333–346, 2008. View at Publisher · View at Google Scholar · View at Scopus